AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19120322 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetics
Number of subjects: 207
Study 17714328 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) task
Number of subjects: 8
Study 17714328 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects with no history of neurological deficits)
Number of subjects: 8
Study 15021220 — intervention group
Group type: EXPERIMENTAL
Intervention: argon laser trabeculoplasty plus betaxolol
Number of subjects: 255
Study 15021220 — intervention group
Group type: COMPARATOR
Intervention: no immediate treatment
Number of subjects: 255
Study 11500608 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 60 mg once daily
Number of subjects: 62
Study 11500608 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 62
Study 10036122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative pre-conditioning of laparoscopic gas with the Insuflow device
Number of subjects: 72
Study 10036122 — intervention group
Group type: COMPARATOR
Intervention: Standard raw gas
Number of subjects: 72
Study 7974373 — intervention group
Group type: EXPERIMENTAL
Intervention: CRVO patients
Number of subjects: 40
Study 7974373 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ischemic CRVO patients
Number of subjects: 40
Study 7974373 — intervention group
Group type: EXPERIMENTAL
Intervention: CRVO patients with Lp(a) > 300 mg/l
Number of subjects: 40
Study 7974373 — intervention group
Group type: EXPERIMENTAL
Intervention: CRVO patients with high Lp(a)
Number of subjects: 40
Study 7974373 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 40
Study 2557950 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA sutures
Number of subjects: 28
Study 2557950 — intervention group
Group type: COMPARATOR
Intervention: PDS sutures
Number of subjects: 28
Study 1157027 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy with VAC for patients with embryonal carcinoma of the ovary
Number of subjects: 0
Study 1157027 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with VAC for advanced embryonal carcinoma of the ovary
Number of subjects: 0
Study 1157027 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined irradiation and chemotherapy with vincristine and actinomycin-D
Number of subjects: 0
Study 1157027 — intervention group
Group type: COMPARATOR
Intervention: Postoperative irradiation therapy
Number of subjects: 0
Study 31331789 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg up to 150 mg every 2 weeks [COMBO I & II] or 150 mg every 2 weeks [LONG TERM])
Number of subjects: 4389
Study 31331789 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4389
Study 31331789 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo [COMBO I and LONG TERM] or ezetimibe [COMBO II])
Number of subjects: 4389
Study 27793576 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical Beliefs Questionnaire (TBQ)
Number of subjects: 394
Study 25783958 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% ASiR dataset
Number of subjects: 40
Study 25783958 — intervention group
Group type: COMPARATOR
Intervention: Filtered backprojection algorithm and ASiR (20%, 40%, 60%, and 80% blending)
Number of subjects: 40
Study 22304242 — intervention group
Group type: COMPARATOR
Intervention: Dietary protein level at 28%
Number of subjects: 60
Study 22304242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein level at 34%
Number of subjects: 60
Study 22304242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein levels (28%, 30%, 32%, 34%, 36%, 38%)
Number of subjects: 60
Study 22151475 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion style acupuncture treatment (MSAT)
Number of subjects: 0
Study 22151475 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti‐inflammatory drug (NSAID) injection (diclofenac)
Number of subjects: 0
Study 19107530 — intervention group
Group type: EXPERIMENTAL
Intervention: ABG alone
Number of subjects: 13
Study 19107530 — intervention group
Group type: COMPARATOR
Intervention: ABG and PDLG
Number of subjects: 13
Study 17694218 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of 1% ropivacaine gel (ropivacaine‐20)
Number of subjects: 30
Study 17694218 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of 1% ropivacaine gel (ropivacaine‐60)
Number of subjects: 30
Study 17694218 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of EMLA cream (EMLA‐20)
Number of subjects: 30
Study 17694218 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of EMLA cream (EMLA‐60)
Number of subjects: 30
Study 17694218 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of benzocaine gel (benzocaine‐20)
Number of subjects: 30
Study 17694218 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of benzocaine gel (benzocaine‐60)
Number of subjects: 30
Study 15154956 — intervention group
Group type: EXPERIMENTAL
Intervention: Group care
Number of subjects: 900
Study 15154956 — intervention group
Group type: COMPARATOR
Intervention: Individual care
Number of subjects: 900
Study 11799841 — intervention group
Group type: EXPERIMENTAL
Intervention: New bromazepam slow-release formulation
Number of subjects: 24
Study 11799841 — intervention group
Group type: COMPARATOR
Intervention: Conventional bromazepam formulation
Number of subjects: 24
Study 9516090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa 2.5 mg daily for 2 weeks via Medic‐Aid Durable SideStream nebulizer (MMAD 2.1 microm)
Number of subjects: 749
Study 9516090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa 2.5 mg daily for 2 weeks via Hudson T Up‐draft nebulizer (MMAD 4.9 microm)
Number of subjects: 749
Study 9516090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa via Medic‐Aid Durable SideStream nebulizer
Number of subjects: 749
Study 8194024 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide 25 mg/m2/day
Number of subjects: 40
Study 8194024 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide 20 mg/m2/day
Number of subjects: 40
Study 2721849 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickness Impact Profile (SIP) completed by patients and physicians
Number of subjects: 0
Study 2721849 — intervention group
Group type: EXPERIMENTAL
Intervention: SIP reviewed by physicians prior to visit
Number of subjects: 0
Study 2721849 — intervention group
Group type: EXPERIMENTAL
Intervention: SIP usage in clinic
Number of subjects: 0
Study 2721849 — intervention group
Group type: EXPERIMENTAL
Intervention: SIP length
Number of subjects: 0
Study 4394369 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 0
Study 4394369 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 0
Study 31791323 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care intervention including a sexual health self-assessment with embedded clinical prediction tool predicting STI positivity and personalized messaging with key steps to lower risk for STIs
Number of subjects: 0
Study 31791323 — intervention group
Group type: COMPARATOR
Intervention: Control condition including a self-assessment about water, soda and sugar sweetened beverage consumption and personalized messaging to meet recommended daily intake
Number of subjects: 0
Study 29366739 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-based microtenotomy
Number of subjects: 46
Study 29366739 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic release
Number of subjects: 46
Study 26660720 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + PDT (scaling and root planing combined with photodynamic therapy using methylene blue as a photosensitizer)
Number of subjects: 15
Study 26660720 — intervention group
Group type: COMPARATOR
Intervention: SRP (scaling and root planing alone)
Number of subjects: 15
Study 26660720 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + PDT
Number of subjects: 15
Study 23780898 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic (IT: 110% of maximal isometric torque)
Number of subjects: 16
Study 23780898 — intervention group
Group type: COMPARATOR
Intervention: Isokinetic (IK: 120°/s)
Number of subjects: 16
Study 21435821 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain-clamping method using tranexamic acid and carbazochrome sodium sulfonate hydrate
Number of subjects: 100
Study 21435821 — intervention group
Group type: COMPARATOR
Intervention: Drain-clamping with saline
Number of subjects: 100
Study 19347928 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% dexamethasone sodium phosphate iontophoresis
Number of subjects: 17
Study 19347928 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 17
Study 17883519 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan orally disintegrating tablets (ODT) 2.5 mg
Number of subjects: 48
Study 17883519 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 5 mg
Number of subjects: 48
Study 17883519 — intervention group
Group type: COMPARATOR
Intervention: Conventional zolmitriptan tablets 2.5 mg
Number of subjects: 48
Study 17883519 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan (all formulations)
Number of subjects: 48
Study 16284584 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TDF)
Number of subjects: 680
Study 16284584 — intervention group
Group type: COMPARATOR
Intervention: Sustained release morphine (SRM)
Number of subjects: 680
Study 12139679 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% methylprednisolone aceponate milk (MPA)
Number of subjects: 24
Study 12139679 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% hydrocortisone 17‐butyrate emulsion (HCB)
Number of subjects: 24
Study 12139679 — intervention group
Group type: COMPARATOR
Intervention: Untreated area
Number of subjects: 24
Study 9464749 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HTS)
Number of subjects: 34
Study 9464749 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LRS)
Number of subjects: 34
Study 7716196 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine (100 mg/kg of body weight)
Number of subjects: 20
Study 7716196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2757879 — intervention group
Group type: COMPARATOR
Intervention: Flosequinan
Number of subjects: 12
Study 2757879 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 12
Study 779751 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline (5 mg)
Number of subjects: 18
Study 779751 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol fenoterol (400 micrograms)
Number of subjects: 18
Study 779751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31064877 — intervention group
Group type: EXPERIMENTAL
Intervention: Police body-worn cameras (BWCs)
Number of subjects: 2224
Study 29798542 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral retinacular release
Number of subjects: 126
Study 29798542 — intervention group
Group type: COMPARATOR
Intervention: Control (no lateral retinacular release)
Number of subjects: 126
Study 25385408 — intervention group
Group type: EXPERIMENTAL
Intervention: Group fitness class for pregnant women, 60 min class with 40 min endurance training and 20 min strength training, performed at least twice per week for a minimum of 12 weeks
Number of subjects: 105
Study 25385408 — intervention group
Group type: EXPERIMENTAL
Intervention: Group fitness class for pregnant women
Number of subjects: 105
Study 25385408 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 105
Study 23933545 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 7.5 mg twice a day
Number of subjects: 275
Study 23933545 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 275
Study 22136094 — intervention group
Group type: EXPERIMENTAL
Intervention: ER d‐MPH (10, 20, 25‐30 mg)
Number of subjects: 56
Study 22136094 — intervention group
Group type: EXPERIMENTAL
Intervention: ER MAS (10, 20, 25‐30 mg)
Number of subjects: 56
Study 22136094 — intervention group
Group type: COMPARATOR
Intervention: Placebo (randomized within each drug period)
Number of subjects: 56
Study 18583015 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-calls
Number of subjects: 6
Study 18583015 — intervention group
Group type: COMPARATOR
Intervention: Traditional phone calls
Number of subjects: 6
Study 16780389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 0
Study 16780389 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 0
Study 14518664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine alone (200 mg daily)
Number of subjects: 276
Study 14518664 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine plus aspirin (100 mg daily plus 81 mg daily)
Number of subjects: 276
Study 11193512 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection speed of 0.2 ml/sec
Number of subjects: 100
Study 11193512 — intervention group
Group type: COMPARATOR
Intervention: Injection speed of 0.03 ml/sec
Number of subjects: 100
Study 9178459 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine, 180 ELISA units per dose
Number of subjects: 110
Study 9178459 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine, 360 ELISA units per dose
Number of subjects: 110
Study 9178459 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine, 720 ELISA units per dose
Number of subjects: 110
Study 1488568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol/ipratropium bromide combination (Berodual) inhaled as a dry powder
Number of subjects: 38
Study 1488568 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol/ipratropium bromide combination (Berodual) by metered dose inhaler (MDI)
Number of subjects: 38
Study 2859653 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine in the evening
Number of subjects: 131
Study 2859653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 31302868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 608
Study 31302868 — intervention group
Group type: COMPARATOR
Intervention: Control (non-exposed cohort)
Number of subjects: 608
Study 30219062 — intervention group
Group type: EXPERIMENTAL
Intervention: High zinc biofortified wheat flour (HZn, 30 ppm zinc daily)
Number of subjects: 6005
Study 27454662 — intervention group
Group type: EXPERIMENTAL
Intervention: ETORICOX-PREOP group received etoricoxib 120 mg orally 1 h before surgery
Number of subjects: 165
Study 27454662 — intervention group
Group type: EXPERIMENTAL
Intervention: ETORICOX-POSTOP group received etoricoxib 120 mg at the end of surgery
Number of subjects: 165
Study 27454662 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO group received placebo pills
Number of subjects: 165
Study 27454662 — intervention group
Group type: EXPERIMENTAL
Intervention: ETORICOX-PREOP group
Number of subjects: 165
Study 27454662 — intervention group
Group type: EXPERIMENTAL
Intervention: ETORICOX-POSTOP group
Number of subjects: 165
Study 27454662 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 165
Study 23811290 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-ppm nanoscale silver particle solution
Number of subjects: 60
Study 23811290 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-ppm nanoscale silver particle solution
Number of subjects: 60
Study 23011002 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow spectacle lenses worn for 3 months
Number of subjects: 82
Study 23011002 — intervention group
Group type: COMPARATOR
Intervention: Without yellow spectacle lenses (control group)
Number of subjects: 82
Study 20835574 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl
Number of subjects: 30
Study 20835574 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl followed by 17% EDTA
Number of subjects: 30
Study 20835574 — intervention group
Group type: COMPARATOR
Intervention: Control (no irrigating solution)
Number of subjects: 30
Study 18060675 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of n‐3 PUFAs (EPA and DHA)
Number of subjects: 22
Study 18060675 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (placebo)
Number of subjects: 22
Study 15990633 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation (0.3 g/kg per day)
Number of subjects: 102
Study 15990633 — intervention group
Group type: COMPARATOR
Intervention: Control (isonitrogenous placebo supplementation with alanine)
Number of subjects: 102
Study 12969111 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 60
Study 12969111 — intervention group
Group type: COMPARATOR
Intervention: HES 200/0.5
Number of subjects: 60
Study 10740553 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 90
Study 10740553 — intervention group
Group type: COMPARATOR
Intervention: 0.75% bupivacaine and 2% lidocaine mixture
Number of subjects: 90
Study 9217906 — intervention group
Group type: EXPERIMENTAL
Intervention: Training video on death certification
Number of subjects: 185
Study 1394916 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole (400mg, single dose)
Number of subjects: 0
Study 1394916 — intervention group
Group type: EXPERIMENTAL
Intervention: mebendazole composite (mebendazole 100 mg and levamisole 25mg bid x 3d)
Number of subjects: 0
Study 1394916 — intervention group
Group type: EXPERIMENTAL
Intervention: oxantel pyrantel pamoate composite (pyrantel pamoate 150 mg and oxantel pamoate 150 mg bid x 2d)
Number of subjects: 0
Study 1394916 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrantel pamoate composite (base 10 mg/kg, single dose)
Number of subjects: 0
Study 3966851 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment groups with negative affective style (AS)
Number of subjects: 0
Study 3966851 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based family treatment groups with negative affective style (AS)
Number of subjects: 0
Study 29039979 — intervention group
Group type: EXPERIMENTAL
Intervention: HLD200 (54 mg)
Number of subjects: 41
Study 25851842 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour educational training focused on communication skills
Number of subjects: 45
Study 25851842 — intervention group
Group type: COMPARATOR
Intervention: Usual care by GPs in control group
Number of subjects: 45
Study 24776175 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching (12 months)
Number of subjects: 441
Study 24776175 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 441
Study 22327707 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (0.5 g twice-daily, enteric)
Number of subjects: 20
Study 22327707 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 20206794 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 30 mg
Number of subjects: 32
Study 20206794 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 300 mg
Number of subjects: 32
Study 17826582 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 424
Study 17826582 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise educational intervention
Number of subjects: 424
Study 16047921 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous LH activity in the form of human menotrophin
Number of subjects: 68
Study 16047921 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous LH activity in the form of human recombinant LH
Number of subjects: 68
Study 16047921 — intervention group
Group type: COMPARATOR
Intervention: Pure recombinant FSH
Number of subjects: 68
Study 12381797 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised active and passive range‐of‐motion exercises
Number of subjects: 19
Study 12381797 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 19
Study 11051233 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO-PCV (alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine)
Number of subjects: 272
Study 11051233 — intervention group
Group type: COMPARATOR
Intervention: PCV (procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine)
Number of subjects: 272
Study 11051233 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO-PCV
Number of subjects: 272
Study 11051233 — intervention group
Group type: COMPARATOR
Intervention: PCV
Number of subjects: 272
Study 9124670 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1 ml (10 mg)
Number of subjects: 58
Study 9124670 — intervention group
Group type: COMPARATOR
Intervention: Intralipid 1 ml (control group)
Number of subjects: 58
Study 8477961 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone with enteral food supplement
Number of subjects: 273
Study 8477961 — intervention group
Group type: COMPARATOR
Intervention: Adequate caloric intake
Number of subjects: 273
Study 3535612 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine-urethane formiate
Number of subjects: 9
Study 3535612 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine lactic acid formiate
Number of subjects: 9
Study 3535612 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine resorcine hydrochloride
Number of subjects: 9
Study 31723080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid training system (HTS)
Number of subjects: 53
Study 31723080 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (Control)
Number of subjects: 53
Study 30264073 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea or cocoa flavanols (exact dosage and duration not specified)
Number of subjects: 0
Study 30264073 — intervention group
Group type: EXPERIMENTAL
Intervention: High cocoa treatment (exact dosage and duration not specified)
Number of subjects: 0
Study 26721220 — intervention group
Group type: EXPERIMENTAL
Intervention: Citron syrup (15 ml, three times daily for 4 weeks)
Number of subjects: 90
Study 26721220 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg tablet, three times daily for 4 weeks)
Number of subjects: 90
Study 26721220 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup (15 ml, three times daily for 4 weeks)
Number of subjects: 90
Study 25373622 — intervention group
Group type: EXPERIMENTAL
Intervention: UDP‐glucuronosyltransferase phenotype for COT
Number of subjects: 260
Study 22659448 — intervention group
Group type: EXPERIMENTAL
Intervention: Agrippal® (trivalent subunit egg-based influenza vaccine)
Number of subjects: 1507